Sinopharm Hyundai announced that the holding subsidiary Sinopharm Group Zhijun (Shenzhen) Pharmaceutical Co., Ltd. passed the consistent evaluation of generic drug quality and efficacy. The drug is suitable for treating severe systemic infections and lower respiratory infections caused by sensitive bacteria. In 2023, global sales of the formulation were US$476 million, and sales of public medical institutions nationwide were 1,921 billion yuan. Sinopharm Zhijun has invested a total of about 6.415 million yuan in R&D. Passing the evaluation will facilitate product market expansion and sales.

Zhitongcaijing · 04/15 08:17
Sinopharm Hyundai announced that the holding subsidiary Sinopharm Group Zhijun (Shenzhen) Pharmaceutical Co., Ltd. passed the consistent evaluation of generic drug quality and efficacy. The drug is suitable for treating severe systemic infections and lower respiratory infections caused by sensitive bacteria. In 2023, global sales of the formulation were US$476 million, and sales of public medical institutions nationwide were 1,921 billion yuan. Sinopharm Zhijun has invested a total of about 6.415 million yuan in R&D. Passing the evaluation will facilitate product market expansion and sales.